阿帕替尼结合替吉奥对晚期胃癌患者血清肿瘤标志物、Th1及Th2类细胞因子水平的影响

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Apatinib combined with Tegafur, Gimeracil and Oteracil Potassium on the levels of serum tumor markers, T helper cell 1 (Th1) and T helper cell 2 (Th2) cell factors in patients with late gastric cancer. Methods The clinical data of 80 patients with late gastric cancer who were admitted to our hospital from January 2017 to December 2019 were retrospectively analyzed and divided into the control group (treated by Tegafur,Gimeracil and Oteracil Potassium) and the observation group (treated by Apatinib combined with Tegafur, Gimeracil and Oteracil Potassium) according to treatment methods, with 40 cases in each group. The serum tumor markers (carcino-embryonic antigen [CEA], carbohydrate antigen 19-9 [CA19-9], carbohydrate antigen 72-4 [CA72-4]), Th1 (interleukin-2 [IL-2] and interferon-γ [IFN-γ]) and Th2 (interleukin-4 [IL-4] and interleukin-10 [IL-10]) cell factors between the two groups before and after treatment were compared. Results The levels of serum CEA, CA19-9, CA72-4,IL-4 and IL-10 in two groups after treatment were lower than those before treatment, and the levels of IL-2 and IFN-γ were higher than those before treatment, and the differences were statistically significant (P＜0.05). The levels of CEA,CA19-9, CA72-4, IL-4 and IL-10 in the observation group after treatment were lower than those in the control group,and the levels of IL-2 and IFN-γ in the observation group were higher than those in the control group, and the differences were statistically significant (P ＜0.05). Conclusion Apatinib combined with Tegafur, Gimeracil and Oteracil Potassium is effective in the treatment of late gastric cancer, it can regulate the levels of serum tumor markers, Th1 and Th2 cell factors in patients, and alleviate the clinical symptoms.

Key words： Late gastric cancer Apatinib Tegafur, Gimeracil and Oteracil Potassium Serum tumor markers T helper cell 1 T helper cell 2

Received: 15 April 2020

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Hong

Cite this article:

ZHANG Hong. Effect of Apatinib combined with Tegafur, Gimeracil and Oteracil Potassium on the levels of serum tumor markers, Th1 and Th2 cell factors in patients with late gastric cancer[J]. 中国当代医药, 2020, 27(29): 77-79.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I29/77

[1]	李月丽，刘军良.替吉奥联合顺铂治疗晚期胃癌的疗效观察[J].中国肿瘤临床与康复，2019，26（8）：971-973.
[2]	吴志伟，蔡俊，陆网坤，等.阿帕替尼联合替吉奥二线治疗晚期胃癌的临床观察[J].中国当代医药，2017，24（23）：69-71，75.
[3]	鲍瑜，钱江，宋文灿，等.阿帕替尼联合替吉奥一线治疗晚期胃癌临床研究[J].中国药业，2019，28（11）：74-77.
[4]	张勤，王鹏，王遵义.阿帕替尼联合替吉奥治疗晚期胃癌1例[J].中国肿瘤临床，2017，44（12）：620.
[5]	俞根华，姚强，张海兵，等.益气健脾方联合替吉奥一线治疗老年晚期胃癌41 例[J].北京中医药，2018，37（4）：318-320，323.
[6]	姚杨，贾英杰，邓仁芬，等.晚期胃癌的维持治疗[J].国际肿瘤学杂志，2019，46（7）：439-442.
[7]	蔡红许，宋竹翠，林灵芝，等.替吉奥联合伊立替康或紫杉醇治疗晚期进展胃癌疗效分析[J].河北医药，2017，39（24）：3754-3756.
[8]	毛灵.替吉奥胶囊治疗晚期胃癌的临床疗效[J].江苏医药，2019，45（1）：63-65.
[9]	杨宁娟，殷常春，潘守杰.阿帕替尼联合替吉奥对老年晚期胃癌的疗效[J].中国临床研究，2019，32（2）：162-165.
[10]	赵凯丰，肖罗，张静，等.替吉奥治疗进展期胃癌的临床疗效分析[J].肿瘤药学，2018，8（5）：732-734.
[11]	康毓芝.检测血清肿瘤标志物对诊断胃癌的临床意义[J].实用癌症杂志，2019，34（5）：721-723.
[12]	张蕾，薛永飞，冀叶，等.胃癌血清肿瘤标志物和HER2表达的临床意义[J].实用肿瘤杂志，2019，34（1）：61-65.
[13]	葛锐，袁艳.复方苦参注射液对胃癌化疗患者Th1/Th2细胞漂移和骨髓抑制的影响[J].河北医药，2019，41（13）：1970-1973.
[14]	纪华清，桂宏亮，束宽山，等.阿帕替尼单药及合用替吉奥治疗晚期胃癌疗效观察[J].海南医学，2019，30（5）：619-621.
[15]	郭军.阿帕替尼联合替吉奥二线治疗70 例晚期胃癌[J].肿瘤学杂志，2019，25（9）：841-843.